EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access · CC BY 4.0

Protocol for the OPTIMSE-1 randomised clinical trial to test specialist-led identification and management of cardio-renal-metabolic-pulmonary disease in machine learning algorithm-detected high-risk community-dwelling individuals

Ramesh Nadarajah, Ali Wahab, Tobin Joseph, Catherine Reynolds, Sheena Bennett, Mohammad Haris, Adam B Smith, Chris Hayward, Jianhua Wu, Chris P Gale

BMJ Open · 2025

DOI: 10.1136/bmjopen-2025-101088 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift BMJ Open, 2025. Verfasst von Ramesh Nadarajah und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of Leeds, Leeds, UK r.nadarajah@leeds.ac.uk. Hauptthemen laut MEDLINE: Atrial Fibrillation, Lung Diseases, Machine Learning. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation, National Institute for Health and Care Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction People identified as higher risk by a machine learning algorithm (Future Innovations in Novel Detection of Atrial Fibrillation [FIND-AF]) are at increased risk of cardio-renal-metabolic-pulmonary disease and cardiovascular death. The OPTIMISE-1 randomised controlled trial aims to test the effect of community-based specialist-led identification and management of cardio-renal-metabolic-pulmonary (CRMP) disease and risk factors compared with usual care on the use of therapeutic interventions over a follow-up of 6 months among high FIND-AF risk community-dwelling individuals. Methods and analysis OPTIMISE-1 is a multicentre, pragmatic, prospective, randomised, open-label, blinded-endpoint strategy trial that will recruit 138 participants aged 30 years or older, with a high FIND-AF risk score and previously enrolled in the FIND-AF pilot study ( NCT05898165 ), to be randomised 1:1 to a specialist-led care intervention or usual care. The primary endpoint is a composite of initiation or increase of guideline-directed CRMP therapies. The secondary endpoints are the components of the primary endpoint, time to primary endpoint, diagnosis of new CRMP diseases or risk factors, time to diagnosis of new CRMP diseases or risk factors, initiation or increase of guideline-directed CRMP therapies for participants with recorded CRMP disease, initiation or increase of guideline-directed CRMP therapies for participants with newly diagnosed CRMP disease and change in participant-reported quality of life. Ethics and dissemination The study has ethical approval (the North East & North Tyneside 2 Research Ethics Committee reference 24/NE/0188). Findings will be announced at relevant conferences and published in peer-reviewed journals in line with the Funder’s open access policy. Trial registration number Clinicaltrials.gov NCT06444711 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationLung DiseasesMachine LearningAdultAgedFemaleHumansMaleAlgorithmsIndependent LivingMulticenter Studies as TopicPragmatic Clinical Trials as TopicProspective StudiesRisk AssessmentRisk FactorsRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Cardiovascular DiseaseClinical TrialElectronic Health RecordsMachine LearningRisk Factors

Autor:innen und Institutionen

  • University of Leeds, Leeds, UK r.nadarajah@leeds.ac.uk.
  • Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Leeds Institute of Data Analytics, Leeds, UK.
  • Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
  • Queen Mary University of London, London, UK.
  • Leeds Teaching Hospitals NHS Trust Department of Cardiology, Leeds, UK.

Förderung

  • British Heart Foundation
  • National Institute for Health and Care Research

Zitieren

APA

Nadarajah, R., Wahab, A., Joseph, T., Reynolds, C., Bennett, S., Haris, M., Smith, A. B., Hayward, C., Wu, J., & Gale, C. P. (2025). Protocol for the OPTIMSE-1 randomised clinical trial to test specialist-led identification and management of cardio-renal-metabolic-pulmonary disease in machine learning algorithm-detected high-risk community-dwelling individuals. BMJ Open. https://doi.org/10.1136/bmjopen-2025-101088

Vancouver

Nadarajah R, Wahab A, Joseph T, Reynolds C, Bennett S, Haris M, et al. Protocol for the OPTIMSE-1 randomised clinical trial to test specialist-led identification and management of cardio-renal-metabolic-pulmonary disease in machine learning algorithm-detected high-risk community-dwelling individuals. BMJ Open. 2025. doi:10.1136/bmjopen-2025-101088

BibTeX
@article{Nadarajah2025,
  author = {Nadarajah, Ramesh and Wahab, Ali and Joseph, Tobin and Reynolds, Catherine and Bennett, Sheena and Haris, Mohammad and Smith, Adam B and Hayward, Chris and Wu, Jianhua and Gale, Chris P},
  title = {Protocol for the OPTIMSE-1 randomised clinical trial to test specialist-led identification and management of cardio-renal-metabolic-pulmonary disease in machine learning algorithm-detected high-risk community-dwelling individuals},
  journal = {BMJ Open},
  year = {2025},
  doi = {10.1136/bmjopen-2025-101088}
}
Kostenlos starten →